BioMérieux: Oddo BHF raises target price

(CercleFinance.com) - While maintaining its 'neutral' rating on bioMérieux shares, Oddo BHF has raised its target price for them from E105 to E113, the day after the presentation of a medium-term roadmap that tends to be above or at the top end of consensus expectations.


Analysts found the company rather confident and explicit, in short rather convincing, on its growth levers and efficiency measures, also noting a surprisingly upbeat stance regarding M&A.

In all, Oddo BHF believes that bioMérieux offers a medium-term plan and visibility, and addresses issues that the market has been waiting for, presents a solid trajectory and manages to demonstrate that scale effects will finally become material.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as decision-making aids for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.